Choline as a biomarker for cell proliferation: Do the results from proton MR spectroscopy show difference between HER2/neu positive and negative breast cancers?

International Journal of Cancer

Volumn 123, Issue 5, 2008, Pages 1219-1221

  Baek, Hyeon Man ^a   Chen, Jeon Hor ^a,b   Nalcioglu, Orhan ^a   Su, Min Ying ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTON; TUMOR MARKER;

ADIPOSE TISSUE; ADULT; BREAST BIOPSY; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; LUNG CARCINOMA; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; STAINING; TUMOR VOLUME; AGED; BREAST TUMOR; CHEMISTRY; METHODOLOGY; MIDDLE AGED; PREDICTION AND FORECASTING;

ADULT; AGED; BREAST NEOPLASMS; CELL PROLIFERATION; CHOLINE; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROTONS; RECEPTOR, ERBB-2; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 47249158124     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23552     Document Type: Letter

References (19)

1. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005;353:1652-4.
2. Brand FX, Ravanel N, Gauchez AS, Pasquier D, Payan R, Fagret D, Mousseau M. Prospect for anti-her2 receptor therapy in breast cancer. Anticancer Res 2006;26:715-22.
3. Ménard S, Casalini P, Campiglio M, Pupa SM, Tagliabue E. Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci 2004;61:2965-78.
4. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001;61Suppl 2:1-13.
5. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003;284:99-110.
6. Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol 2001; 12 Suppl 1:S3-S8.
7. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett 2006;232:123-38.
8. Stefano R, Agostara B, Calabro M, Campisi I, Ravazzolo B, Traina A, Miele M, Castagnetta L. Expression levels and clinical-pathological correlations of HER2/neu in primary and metastatic human breast cancer. Ann N Y Acad Sci 2004;1028:463-72.
9. Tokatli F, Altaner S, Uzal C, Ture M, Kocak Z, Uygun K, Bilgi S. Association of HER-2/neu overexpression with the number of involved axillary lymph nodes in hormone receptor positive breast cancer patients. Exp Oncol 2005;27:145-9.
10. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999;59:80-4.
11. 1H MR spectroscopy to improve diagnostic accuracy of breast MR imaging: preliminary results of observer performance study at 4.0T. Radiology 2005; 236:465-75.
12. Bartella L, Thakur SB, Morris EA, Dershaw DD, Huang W, Chough E, Cruz MC, Liberman L. Enhancing nonmass lesions in the breast: evaluation with proton (1H) MR spectroscopy. Radiology 2007; 245:80-7.
13. Tse GM, Yeung DK, King AD, Cheung HS, Yang WT. In vivo proton magnetic resonance spectroscopy of breast lesions: an update. Breast Cancer Res Treat 2007; 104:249-55.
14. Huang W, Fisher PR, Dulaimy K, Tudorica LA, Ohea B, Mutton TM. Detection of breast malignancy: diagnostic MR protocol for improved specificity. Radiology 2004;232:585-91.
15. Bartella L, Morris EA, Dershaw DD, Liberman L, Thakur SB, Moskowitz C, Guido J, Huang W. Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study. Radiology 2006;239:686-92.
16. Agrawal G, Chen JH, Baik HM, Hsiang D, Mehta RS, Nalcioglu O, Su MY. MR imaging features of breast cancer: a correlation study with HER2/neu receptor. Ann Oncol 2007;18:1903-4.
17. 1H MR Spectroscopy. Magn Reson Med 2003;50:1134-43.
18. Zheng L, Ren JQ, Chen Q, Zhang HP, Zhu HG. The effect of HER2/ neu overexpression on p53 gene expression, cell proliferation and sensitivity to gamma- irradiation via the PI3K/Akt pathway in breast cancer cell MCF7. Zhonghua Zhong Liu Za Zhi 2004;26:594-7.
19. Tse GM, Ceung HS, Pang LM, Chu WC, Law BK, Kung FY, Yeung DK. Characterization of lesions of the breast with proton MR spectroscopy: comparison of carcinomas, benign lesions, and phyllodes tumors. Am J Roentgenol 2003;181:1267-72.